Octreoteva Long Acting (Octreotide Acetate)

Octreotide acetate binds to somatostatin receptors, primarily subtypes sst2 and sst5, on endocrine and neuroendocrine cells. This binding inhibits adenylate cyclase and calcium influx, reducing the secretion of hormones like growth hormone, serotonin, and vasoactive intestinal peptide, thereby mitigating disease activity.

The dosage of Octreoteva Long Acting is individualized by the prescribing clinician based on the specific indication, patient weight, disease severity, and response to therapy. Only a qualified healthcare professional should determine the appropriate dosing regimen.

Octreotide acetate is classified as pregnancy category B; animal studies have not shown risk, but there are limited human data. It should be used during pregnancy only if clearly needed. Breastfeeding is not recommended because the drug may be excreted in milk and could affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain logistics if required), and import documentation.

Octreoteva Long Acting provides prolonged drug exposure with fewer injections compared with short‑acting octreotide formulations. Compared with lanreotide, another long‑acting analog, octreotide has a slightly broader receptor affinity profile, which may influence efficacy in certain neuroendocrine tumors. Choice of therapy depends on clinical response, patient preference, and physician judgment.

Octreoteva Long Acting must be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking. If the temperature rises above the recommended range, discard the product according to local regulations.

Octreoteva Long Acting is given by subcutaneous injection, typically by a healthcare professional. The injection site is rotated to minimize local reactions. The exact administration schedule—such as every 4 weeks—will be determined by the prescribing clinician based on the patient’s condition.

Serious adverse events include severe bradycardia, acute pancreatitis, anaphylactic reactions, hepatic dysfunction, and rare thromboembolic events. Patients should be monitored for signs of these conditions, and therapy should be discontinued if any serious reaction occurs.

Octreoteva Long Acting is contraindicated in patients with known hypersensitivity to octreotide acetate or any excipients in the formulation. Caution is also advised for individuals with severe cardiac conduction disorders, uncontrolled diabetes, or active gallbladder disease.